Clinical use of cardiovascular risk score
Introduction: The American Heart Association has outlined strategic impact goals designed to improve the cardiovascular health of Americans by 20% by the year 2020 including improvements in lifestyle and behavior.
Hypothesis: We assessed the hypothesis that sharing with patients a 7-protein cardiovascular risk score would motivate them to better adhere to cardiovascular risk reduction measures.
Methods: The 7-protein risk score (SomaScan® CVD Secondary Risk Panel, SomaLogic) provides % risk by year for experiencing a cardiovascular event up to 5 years. Patients with stable coronary heart disease received a baseline lifestyle and behavior survey, chart abstraction, and blood draw for the 7-protein risk score. Results were shared with the patient by their physician. One month after receiving the panel results, patients were surveyed on the overall impact of the panel on health, lifestyle, and medication changes.
Results: Among the 198 enrolled patients, 25% had ≥ 20% predicted risk of a cardiovascular event in 5 years. Of the 131 patients with follow-up survey results to date, higher risk patients reported higher rates of desirable lifestyle changes, including healthier diet (Figure 4). Lower risk patients stated they would maintain their lifestyle to remain healthy.
Conclusions: Patients presented with their personal 7-protein cardiovascular risk score were motivated to improve their lifestyle and adherence to medications. The additional motivation from the test results, if sustained long-term, may translate into improved outcomes in patients with coronary heart disease.
More posters
PosterUtility of proteomic trajectories of cardiovascular risk and cardiorespiratory fitness to monitor adverse health states throughout post-COVID-19 illness
Cardiovascular involvement is a prominent observation in patients during the acute phase of COVID-19 infection, as well as in convalescence. However, the etiology, trajectory, and underlying biology of cardiac dysfunction across the spectrum of COVID-19 illness is not fully understood. To address this, the CISCO-19 study (NCT04403607) was formed to investigate the multisystem effects of COVID-19 from hospitalized patients
PosterIdentifying genetic and environmental influences on proteins associated with age, cardiovascular risk, and other endpoints using the SomaScan® Assay
Protein quantitative trait locus pQTL studies identify genetic variants that are statistically associated with protein levels Results from the growing number of pQTL studies can be combined with genome wide association studies to identify proteins that underlie the genetic risk of disease, thus revealing the mechanisms of disease and potential drug targets.
PosterSomaScan® Platform confirmation and performance validation
The SomaScan® Platform for proteomic profiling uses 7288 (7K) SOMAmer® reagents, single stranded DNA aptamers, to 6596 unique Human Protein Targets. The modified aptamer binding reagents1, SomaScan assay2, its performance characteristic for 5k3 and 7k4 content sets, and specificity5,6,7 to human targets have been previously described. We combine profiles of validation and performance metrics with orthogonal confirmation of specificity from published literature to provide a comprehensive view of the specificity and utility of the SomaScan Platform.